| CAS NO: | 116759-35-4 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 20mg | 电议 |
Nexopamilracemate是Nexopamil的外消旋体。Nexopamil是体内血栓形成和体外血小板聚集中的一种联合Ca2+/5-HT2拮抗剂。
| Cas No. | 116759-35-4 |
| 别名 | 奈索帕米 |
| Canonical SMILES | N#CC(C(C)C)(CCCN(CCCCCC)C)C1=CC(OC)=C(OC)C(OC)=C1 |
| 分子式 | C24H40N2O3 |
| 分子量 | 404.59 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca2+/5-HT2 antagonist on thrombus formation in vivo and on platelet aggregation in vitro. Serotonin-induced platelet aggregation in dog platelet-rich plasma (PRP) in vitro is most potently inhibited by Nexopamil (IC50 81 nM) [1]. Nexopamil (0.05 mg/kg) completely abolishes cyclic flow reductions (CFRs) during the first 30 min after application without significantly altering hemodynamics[1]. [1]. Kirchengast M, et al. Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. |
m.cnreagent.com